Literature DB >> 21981762

Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease--a population-based study.

C Jakobsen1, J Bartek, V Wewer, I Vind, P Munkholm, R Groen, A Paerregaard.   

Abstract

BACKGROUND: Few studies have compared phenotype and disease course in children and adults with inflammatory bowel disease (IBD). AIM: To compare phenotype, treatment and disease course in children (<15 years) and adults (≥18 years) with IBD.
METHODS: Two population-based cohorts comprising paediatric (2001-2006) and adult (2003-2004) patients from Copenhagen County and City were studied.
RESULTS: Twenty children and 106 adults with ulcerative colitis (UC), and 29 children and 67 adults with Crohn's disease (CD) were included. Median follow-up time was 4.8 years (children) and 5.2 years (adults). Children with UC had more extensive disease compared to adult patients [14 (70%) vs. 20 (19%), P<0.001]. The risks of starting systemic steroid treatment and AZA/MP were higher for paediatric UC patients compared to adult UC patients; hazard ratio (HR): 3.1 (95% CI: 1.8-5.3) and HR: 2.5 (1.3-5-9), respectively. Steroid dependency was more frequent in paediatric than in adult UC patients [9 (45%) vs. 9 (8%), P<0.001]. Mild disease course was less frequent in children with UC compared to adult patients [7 (35%) vs. 76 (72%), P=0.002]. Paediatric and adult CD patients did not differ regarding treatment or disease course. Cumulative 5-year surgery rates for paediatric and adult patients were 5% and 9% for UC (N.S.) and 18% and 21% for CD (N.S.), respectively.
CONCLUSIONS: Paediatric UC patients had more extensive disease, were more often treated with systemic steroids and AZA, had a higher frequency of steroid dependency and a more severe disease course compared to adult UC patients. No differences were found when comparing paediatric and adult CD patients.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21981762     DOI: 10.1111/j.1365-2036.2011.04857.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  28 in total

1.  Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients.

Authors:  Jason M Shapiro; Sarah E Hagin; Samir A Shah; Renee Bright; Meaghan Law; Heather Moniz; Julie Giacalone; Taylor Jackvony; Sasha Taleban; Zahid Samad; Marjorie Merrick; Bruce E Sands; Neal S LeLeiko
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

Review 2.  Pediatric ulcerative colitis: a practical guide to management.

Authors:  Brian P Regan; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

3.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

4.  Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry.

Authors:  Stephan Buderus; Dietmar Scholz; Rolf Behrens; Martin Classen; Jan De Laffolie; Klaus-Michael Keller; Klaus-Peter Zimmer; Sibylle Koletzko
Journal:  Dtsch Arztebl Int       Date:  2015-02-20       Impact factor: 5.594

5.  Inflammatory Bowel Disease Across the Age Continuum: Similarity and Disparity.

Authors:  Amey Dilip Sonavane; Pratibha Sonawane; Deepak N Amarapurkar
Journal:  Indian J Pediatr       Date:  2018-03-23       Impact factor: 1.967

Review 6.  Very early-onset inflammatory bowel disease: gaining insight through focused discovery.

Authors:  Christopher J Moran; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

Review 7.  Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis.

Authors:  G Pellino; D S Keller; G M Sampietro; M Carvello; V Celentano; C Coco; F Colombo; A Geccherle; G Luglio; M Rottoli; M Scarpa; G Sciaudone; G Sica; L Sofo; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-03-02       Impact factor: 3.781

8.  Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.

Authors:  Serena Pastore; Samuele Naviglio; Arianna Canuto; Loredana Lepore; Stefano Martelossi; Alessandro Ventura; Andrea Taddio
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

9.  Colonic epithelial miR-31 associates with the development of Crohn's phenotypes.

Authors:  Benjamin P Keith; Jasmine B Barrow; Takahiko Toyonaga; Nevzat Kazgan; Michelle Hoffner O'Connor; Neil D Shah; Matthew S Schaner; Elisabeth A Wolber; Omar K Trad; Greg R Gipson; Wendy A Pitman; Matthew Kanke; Shruti J Saxena; Nicole Chaumont; Timothy S Sadiq; Mark J Koruda; Paul A Cotney; Nancy Allbritton; Dimitri G Trembath; Francisco Sylvester; Terrence S Furey; Praveen Sethupathy; Shehzad Z Sheikh
Journal:  JCI Insight       Date:  2018-10-04

Review 10.  History of and current issues affecting surgery for pediatric ulcerative colitis.

Authors:  Keiichi Uchida; Toshimitsu Araki; Masato Kusunoki
Journal:  Surg Today       Date:  2012-12-01       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.